Taspoglutide, a Once-Weekly Human GLP-1 Analog, Reduces Appetite and Promotes Weight Loss in Patients With Type 2 Diabetes (T2D): Phase 3 Trial Versus Sitagliptin and Placebo (T-Emerge 4)

被引：0
|
作者：
Bergenstal, Richard
Forti, Adriana
Chiasson, Jean-Louis
Woloschak, Mike
Boldrin, Mark
Leiter, Lawrence
Balena, Raffaella
机构：
来源：
OBESITY | 2010年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S156 / S156
页数：1
相关论文
共 50 条
  • [21] Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Once-Weekly Dulaglutide in Elderly Patients with Type 2 Diabetes (T2D)
    Loghin, Corina
    Schneck, Karen B.
    Cui, Xuewei
    Chien, Jenny Y.
    DIABETES, 2015, 64 : A259 - A259
  • [22] The role of GLP-1 in type 2 diabetes (T2D): effects of DPP-4 inhibition and GLP-1 receptor blockade
    Aulinger, B. A.
    de Heer, J.
    Bedorf, A.
    Kutscherauer, G.
    Goeke, B.
    Schirra, J.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2014, 122 (03)
  • [23] Taspoglutide added to metformin provides comparable glycaemic control as insulin glargine with superior weight loss and less hypoglycaemia in type 2 diabetes: The T-emerge 5 Trial
    Ampudia-Blasco, F. J.
    Nauck, M.
    Andjelkovic, M.
    Horton, E.
    Boldrin, M.
    Balena, R.
    DIABETOLOGIA, 2010, 53
  • [24] Efficacy and Safety of Taspoglutide in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Plus Pioglitazone over 24 Weeks: T-Emerge 3 Trial
    Henry, Robert R.
    Mudaliar, Sunder
    Kanitra, Linda
    Woloschak, Michael
    Balena, Raffaella
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (07): : 2370 - 2379
  • [25] Efficacy and safety of once-weekly GLP-1 RA in patients with type 2 diabetes treated with DPP-4 inhibitor
    Murakami, Masako
    Hirahara, Naoko
    Morita, Hiroshi
    Sasaki, Shigekazu
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S105 - S105
  • [26] Taspoglutide, a human once-weekly GLP-1 analogue, reduces post-challenge secretion of peptide YY and glucose-dependent insulinotropic peptide in an animal model of type 2 diabetes
    Sewing, S.
    Benardeau, A.
    Migliorini, C.
    Tobalina, L.
    Sebokova, E.
    DIABETOLOGIA, 2009, 52 : S312 - S313
  • [27] The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbA1c and body weight in patients with type 2 diabetes
    Nauck, M. A.
    Petrie, J. R.
    Sesti, G.
    Mannucci, E.
    Courreges, J-P
    Atkin, S.
    Duering, M.
    Jensen, C. B.
    Heller, S.
    DIABETOLOGIA, 2012, 55 : S7 - S7
  • [28] Postprandial glucose levels and long-term glucose control are improved with taspoglutide, a human once-weekly GLP-1 analogue, in an animal model of type 2 diabetes
    Sebokova, E.
    Sewing, S.
    Sprecher, U.
    Tobalina, L.
    Benardeau, A.
    Migliorini, C.
    DIABETOLOGIA, 2009, 52 : S308 - S308
  • [29] Efficacy and safety of PEX168, a novel once-weekly GLP-1 RA, for monotherapy in patients with type 2 diabetes: a phase 3a study
    Yang, W.
    Ji, Q.
    Shan, Z.
    Zhang, Q.
    Li, Y.
    Li, X.
    Qin, G.
    DIABETOLOGIA, 2019, 62 : S367 - S367
  • [30] Switching from the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide Further Improves Glycemic Control and Weight Loss in Patients with Type 2 Diabetes
    Pratley, Richard
    Nauck, Michael
    Bailey, Timothy
    Montanya, Eduard
    Filetti, Sebastiano
    Garber, Alan
    Thomsen, Anne B.
    Hartvig, Helle
    Davies, Melanie
    DIABETES, 2011, 60 : A307 - A308
12345